AAV Edge System | Asimov

Speak to the team

Develop gene therapies with greater precision, quality, and scalability

Speak to the team

Speak to the team

Speak to the team

OVERVIEW

AAV Edge: A suite of tools to advance gene therapy design and production

Upgraded gene therapy development
Asimov’s AAV Edge System is a modular suite of technologies to optimize the design and manufacture of AAV gene therapies. Developers and manufacturing organizations can access the tools that best address their payload design and production needs in one place.

Scalable manufacturing
Fully stable AAV producer cell lines achieve up to 6E15 vg/L before purification, enabling greater control over cost, quality, and scalability. Alternatively, move fast with our optimized transient system.

Engineer smarter payloads
Leverage our genetic and computational toolkit for tissue-specific expression, reduced transgene toxicity during production, and increased in vivo potency.

Payload Design

Production System

Lv Edge Packaging System Schematic

Stable AAV Production

Semi-Stable AAV Production

Transient AAV Production

Fully stable HEK293 producer cell lines with custom capsid and transgene
No transfection required, just add inducer
Optimized production protocols

Semi-Stable HEK293 cell lines
One plasmid transfection with no inducer required
Optimized production protocols

Robust HEK293 cell lines
Transient plasmid system
Optimized production protocols

COMING SOON

We provide tools for you to develop a cell line

We will ship the software, cells, and genes you need to design your cell line in-house.

You design DNA

You use our software to design and optimize genetic constructs using best-in-class parts and models.

We build DNA

We will ship the software, cells, and genes you need to design your cell line in-house.

You transfect cells

You transfect and generate stable cell lines and use our software for data analysis.

You request producer cells

You request a producer cell line for a biologic or gene therapy.

We do cell line development

We do cell line development and process development at our site.

We share progress

We share progress and data with you using  our software.

We ship you producer cell banks

We ship you clonal cell banks and transfer the process to your site.

Payload Design

Production System

Stable AAV Production

Semi-Stable AAV Production

Transient AAV Production

Fully stable HEK293 producer cell lines with custom capsid and transgene
No transfection required, just add inducer
Optimized production protocols

Semi-Stable HEK293 cell lines
One plasmid transfection with no inducer required
Optimized production protocols

Robust HEK293 cell lines
Transient plasmid system
Optimized production protocols

COMING SOON

Stable AAV: Setting a New Standard for Viral Vector Manufacturing

High performance stable cell lines

Low COGS: Lower cost of goods through high-titer, scalable manufacturing that can reduce cost per dose

Reduced risk: Streamline operations by eliminating GMP plasmids required for transient transfection, simplifying production, and derisking the supply chain

Increased manufacturing control: Greater consistency from clonal stable lines reduces variability within a batch as well as across batches

Fast timeline: Custom Stable AAV Producer cell lines in 20 weeks.

High performance across multiple CAR transgenes

E12 titer with eGFP using 2-plasmid system

2-plasmid system outperforms 3-plasmid system across both titer and % full, while reducing GMP plasmid cost.

anti-BCMA Car LV

8.3E7 TU/mL

Yescarta CAR LV

1.1E8 TU/mL

Kymriah CAR LV

1.5E8 TU/mL

Kymriah case study:
LV Edge Packaging System vs transient

The LV Edge Packaging outperforms commercially-available systems.

Titers: Codon optimization of the CDS results in a 5-fold improvement in functional titer and 10-fold improvement of the infectivity ratio. As expected, both LV Edge Packaging and standard four-plasmid systems both show increased titers from sequence optimization.

Variability: Lentiviral production from a single-plasmid transfection results in reduced inter-batch variability versus the standard four-plasmid process. Importantly, the observed reduction in variability is maintained across the different sequence-optimized transfer plasmids.

Kymriah case study: LV Edge Packaging System vs transient

Contact us

Speak to a member of our team

I am interested in accessing the LV Edge System

First name

Last name

Email

Company

Country

Message

I have read and agree to asimov.com’s Terms of Service and Privacy Policy

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form

CONTACT US

We're hiring at the intersection of biology, engineering, and machine learning.

Asimov team at their Boston office

Illustration of a white blood cell

aav STABLE production SYSTEM

Stable AAV Production

Raise manufacturing standards and unlock commercially readiness from the start with custom, high titer AAV Stable Producer HEK293 cell lines.

AAV Edge Stable Producer Cell Lines achieve titers up to 6E15 vg/L and can be delivered within 20 weeks for your payload and capsid of choice.

Lv Edge Producer System Schematic

Why choose AAV Edge Stable Producer Cell Lines?

Low COGS

Lower cost of goods through high-titer, scalable manufacturing that can reduce cost per dose
‍

Reduced risk

Streamline operations by eliminating GMP plasmids required for transient transfection, simplifying production, and derisking the supply chain

Increased manufacturing control

Greater consistency from clonal stable lines reduces variability within a batch as well as across batches
‍

Production system performance

High performance stable cell lines

Fully stable AAV producer cell lines to improve scalability, safety, and consistency. Cell lines achieve titers up to 6E15 vg/L.

High performance across multiple CAR transgenes

E12 titer with eGFP using 2-plasmid system

2-plasmid system outperforms 3-plasmid system across both titer and % full, while reducing GMP plasmid cost.

anti-BCMA Car LV

8.3E7 TU/mL

Yescarta CAR LV

1.1E8 TU/mL

Kymriah CAR LV

1.5E8 TU/mL

Kymriah case study:
LV Edge Packaging System vs transient

The LV Edge Packaging outperforms commercially-available systems.

Titers: Codon optimization of the CDS results in a 5-fold improvement in functional titer and 10-fold improvement of the infectivity ratio. As expected, both LV Edge Packaging and standard four-plasmid systems both show increased titers from sequence optimization.

Variability: Lentiviral production from a single-plasmid transfection results in reduced inter-batch variability versus the standard four-plasmid process. Importantly, the observed reduction in variability is maintained across the different sequence-optimized transfer plasmids.

Kymriah case study: LV Edge Packaging System vs transient

How it works

Transfer

Sequence transfer

You request cell line development for your desired capsid and gene of interest (GOI) and provide us with their sequences. Optionally, we can use our design software, Kernel, to codon optimize the GOI sequence.

CLD start

Suspension-adapted stable pool generation

Asimov generates stable pools by transfecting customized plasmids and selecting for integrants. All work is performed at our state-of-the-art facility in Boston.

Design

12 weeks

Manufacture

Single cell printing and clone screening

Single cell clones are printed from suspension-adapted pools, with monoclonality verification via pre- and post-deposition imaging using the Cytena F-sight™ and Solentim Cell Metric®. We use a proprietary screening method to enrich for high-performance clones.

16 weeks

Ambr®15 screen and optional scale-up

Clones are characterized in Ambr®15 bioreactors. Optionally, model-driven process optimization can be performed at larger scales to further improve performance.

Ship

20 weeks

Manufacture

Research Cell Bank (RCB) release

We ship the top clones as RCBs to you or your preferred manufacturing partner.

What you get

Top 5 clones

Producer cell lines for your AAV gene therapy of interest

Platform process

Optimized platform process compatible with off-the-shelf consumables

CMC-compliant documentation

Plus a platform process to culture cells at your facility

Contact us

Speak to a member of our team

I am interested in accessing the LV Edge Producer System

First name

Last name

Company

Email

Country

Message

I have read and agree to asimov.com’s Terms of Service and Privacy Policy

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form

// Old script // // $(document).ready(function() { // $(".tab-button").click(function(e) { // e.preventDefault(); // const targetTab = $(this).data("tab"); // $(".tab-button").removeClass("tab-button-active"); // $(`.w-tab-link[data-tab='${targetTab}']`).click(); // $(this).addClass("tab-button-active"); // }); // });